Buccal Drug Delivery System Global Market Report 2023
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Buccal Drug Delivery System Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global buccal drug delivery systems market is expected to grow from $2.97 billion in 2022 to $2.97 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The buccal drug delivery systems market is expected to grow to $4.76 billion in 2027 at a CAGR of 9.7%.
Investments in injectable drug delivery systems are a key trend gaining popularity in the buccal drug delivery systems market. Major pharmaceutical companies are investing in drug delivery systems to sustain their position in the market. For instance, in September 2021, Novartis, a Switzerland-based pharmaceutical company invested approximately $40 million in Credence MedSystems, a US-based company that develops innovative drug delivery systems. The aim of the investment is to boost the production of injectable drug delivery systems.
In November 2020, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Emisphere Technologies for a total amount of $ 1.8 billion. With this acquisition, Novo Nordisk eliminates any future royalty liabilities to Emisphere and MHR and gains full access to the Eligen SNAC technology platform, which enables it to diversify its oral drug portfolio assets across therapeutic areas. Emisphere Technologies is a US-based drug delivery company that develops improved oral formulations and active pharmaceutical ingredients.
North America was the largest region in the buccal drug delivery systems market in 2022. The countries covered in the buccal drug delivery system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The rising prevalence of chronic diseases is expected to propel the growth of the buccal drug delivery systems market going forward. Chronic diseases refer to ailments that persist for a year or longer, such as cancer, heart disease, stroke, diabetes, cancer, and arthritis. These are the most prevalent chronic illnesses that can be managed but not cured and necessitate continuous nutrition and medical care. Buccal drug delivery systems provide appropriate and effective drug delivery for administering mucosal and transmucosal drugs that are required by several patients suffering from chronic diseases such as diabetes, and cancer patients.
For instance, in September 2020, according to a study report issued by American Action Forum, chronic illness frequency and expenses are increasing in the United States. Chronic illness is anticipated to continue increasing as the illness incidence among children and young people increases. Chronic illness is a significant healthcare issue since it costs the US $3.7 trillion annually, or about 19.6% of the GDP, and is rising. Therefore, the rising prevalence of chronic diseases drives the buccal drug delivery systems market.
The buccal drug delivery system market consists of the sales of drug ingredients such as insulin, nicotine, tizanidine, triptan, nifedipine, flurbiprofen, sodium carboxymethylcellulose, carbopol, glibenclamide, hyaluronic acid, and xanthan gum.
Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
A selection of companies mentioned in this report includes
Teva Pharmaceuticals Limited
Pfizer Incorporated
GlaxoSmithKline Public Limited Company
Indivior Pharmaceuticals
Generex Biotechnology
Catalent
Arx Limited Liability Company
BioDelivery Science International Incorporated
Cynapsus Therapeutics Incorporated
Endo Pharmaceuticals Public Limited Company
MedLab
AstraZeneca
F. Hoffmann-La Roche Limited
Dr. Reddy's Laboratories Ltd
Takeda Pharmaceutical Company Limited.
Novartis AG
Novo Nordisk A/S
Key Topics Covered:
1. Executive Summary
2. Buccal Drug Delivery System Market Characteristics
3. Buccal Drug Delivery System Market Trends And Strategies
4. Buccal Drug Delivery System Market - Macro Economic Scenario
4.1. COVID-19 Impact On Buccal Drug Delivery System Market
4.2. Ukraine-Russia War Impact On Buccal Drug Delivery System Market
4.3. Impact Of High Inflation On Buccal Drug Delivery System Market
5. Buccal Drug Delivery System Market Size And Growth
5.1. Global Buccal Drug Delivery System Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Buccal Drug Delivery System Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Buccal Drug Delivery System Market Segmentation
6.1. Global Buccal Drug Delivery System Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Sublingual
Buccal Tablets and Lozenges
Oral Sprays
6.2. Global Buccal Drug Delivery System Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Pain Management
Smoking Cessation
Angina Pectoris
6.3. Global Buccal Drug Delivery System Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Hospitals
Ambulatory Centers
Other End-Users
7. Buccal Drug Delivery System Market Regional And Country Analysis
7.1. Global Buccal Drug Delivery System Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Buccal Drug Delivery System Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/ssq0er
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
